Compounds > 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol
Page last updated: 2024-11-06

3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol: synthetic surrogate of tetrahydrocannabinol; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36276
CHEMBL ID3244434
SCHEMBL ID11737062
MeSH IDM0050696

Synonyms (44)

Synonym
ea 1476
.delta.3,4-dimethylheptyltetrahydrocannabinol
nsc25516
dmhp
32904-22-6
nsc-25516
dimethylheptyl-.delta.6a-10a-tetrahydrocannabinol
abbott 40824
6h-dibenzo[b, 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-
sp 8
7,8,9,10-tetrahydro-3-(1,2-dimethylheptyl)-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol
6h-dibenzo(b,d)pyran-1-ol, 7,8,9,10-tetrahydro-3-(1,2-dimethylheptyl)-6,6,9-trimethyl-
delta(3,4)-dimethylheptyltetrahydrocannabinol
dimethylheptylpyran
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydrocannabinol
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol
brn 0313640
dimethylheptyl-delta6a,10a-tetrahydrocannabinol
nsc 25516
delta(sup 3)-thc
6,6,9-trimethyl-3-(3-methyloctan-2-yl)-7,8,9,10-tetrahydrobenzo[c]chromen-1-ol
dmhp, 1', 2'
bdbm84896
abt 40824
4-17-00-01571 (beilstein handbook reference)
unii-944o1ka97g
a-40824
944o1ka97g ,
CHEMBL3244434
QBEFIFWEOSUTKV-UHFFFAOYSA-N
1-hydroxy-3-(3-methyl-2-octyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyran
1-hydroxy-3-(3-methyl-2-octyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6h-dibenzo[ b,d] pyran
SCHEMBL11737062
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h- dibenzo(b,d)pyran-1-ol
abbott-40824
dimethylheptyl-.delta.6a,10a-tetrahydrocannabinol
1-hydroxy-3-(1,2-dimethylheptyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6-dibenzopyran
6h-dibenzo(b,d)pyran-1-ol, 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-
sp-8
ea-1476
alpha-6,10a-dimethylheptyl-tetrahydrocannabinol
Q5277339
DTXSID60954555
6,6,9-trimethyl-3-(3-methyloctan-2-yl)-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyran-1-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1150453Antidepressant activity in mouse assessed as potentiation of dopa-induced motor responses at 5 mg/kg, po pretreated with compound followed by dopa challenge for 4 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149146Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 3 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150468Antianxiety activity in dog assessed as decrease in reactivity and ataxia at 1 mg/kg, po administered as single dose measured every 15 mins for 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149118Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 5 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150457Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1132948Analgesic activity in po dosed mouse by hot plate test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1133558CNS activity in po dosed rat assessed as protection against muricide1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 1. 1-Amino- and 1-mercapto-7,8,9,10-tetrahydro-6H-dibenzo [b,d]pyrans.
AID1149202Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.1 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1133557CNS activity in po dosed septal-lesioned rat assessed as decrease in hyperreactivity behaviour1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 1. 1-Amino- and 1-mercapto-7,8,9,10-tetrahydro-6H-dibenzo [b,d]pyrans.
AID1145567Antihypertensive activity in rat assessed as reduction of blood pressure at 10 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Drugs derived from cannabinoids. 6. Synthesis of cyclic analogues of dimethylheptylpyran.
AID1132947Toxicity in ip dosed Wistar rat assessed as tachycardia1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1145568Antihypertensive activity in rat assessed as reduction of blood pressure at 0.1 mg/kg, po1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Drugs derived from cannabinoids. 6. Synthesis of cyclic analogues of dimethylheptylpyran.
AID1150456Antianxiety activity in albino BALB/cJ mouse assessed as reduction of footshock-induced fighting behavior at 10 mg/kg, po after 90 mins relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149103Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150470Acute toxicity in po dosed Swiss-Webster mouse assessed as mortality measured for 7 days1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149218Acute toxicity in po dosed mouse1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1132949Analgesic activity in po dosed mouse by anti-writhing test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1149166Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149148Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 0.3 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150454Anticonvulsant activity in mouse assessed as protection against audiogenic seizure at 10 mg/kg, po administered for 1 hr prior to testing relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1150469Antianxiety activity in dog assessed as decrease in reactivity and ataxia at 10 mg/kg, po administered as single dose measured every 15 mins for 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1150458Analgesic activity in po dosed mouse by hot-plate test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149134Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 2.5 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149147Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 3 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149203Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.2 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149115Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 10 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150464Sedative-hypnotic activity in cat assessed as increase in total sleep time at 0.5 mg/kg, po administered with diet for 15 to 20 mins measured for 14 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.
AID1149131Antianxiety activity in po dosed dog assessed as ataxia administered as single dose measured up to 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149149Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 0.3 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149116Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 5 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149129Antianxiety activity in po dosed rhesus monkey assessed as antiagressive behavior measured every hour post dosing1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149141Anticonvulsant activity in po dosed mouse assessed as dose required to protect 80% of animal measured after 1 to 4 hrs by audiogenic seizure test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149105Analgesic activity in po dosed Sprague-Dawley rat after 15 to 90 mins by tail flick test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149158Hypnotic activity in cat assessed as increase in total sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1133553CNS activity in po dosed mouse assessed as alteration of exploratory behaviour1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 1. 1-Amino- and 1-mercapto-7,8,9,10-tetrahydro-6H-dibenzo [b,d]pyrans.
AID1149132Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 5 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.95101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		1.9510ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		2.8840benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
abbott 40174
Abbott 40174: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure		2.3620
cannabidiol
Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.		2.0110olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
dimethyl-heptyl tetrahydrocannabinol
dimethyl-heptyl tetrahydrocannabinol: structure given in first source		1.9510
abbott 41988
Abbott 41988: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure		1.9510
diphenoxylate hydrochloride
diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.		1.9510hydrochlorideantidiarrhoeal drug
chloralose
Chloralose: A derivative of CHLORAL HYDRATE that was used as a sedative but has been replaced by safer and more effective drugs. Its most common use is as a general anesthetic in animal experiments.		1.9610
morphine sulfate
[no description available]		1.9510alkaloid sulfate salt
ConditionIndicatedRelationship StrengthStudiesTrials
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		02.3520
Gastric Ulcer
[description not available]		01.9510
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		02.3520
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9510
Absence Seizure
[description not available]		01.9510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9510
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		02.0110